Wellspring Clinic
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Scottsdale, AZ
Scottsdale has one of the country's most saturated longevity and aesthetic medicine markets, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Old Town, North Scottsdale, DC Ranch, and Paradise Valley range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Mayo Clinic Scottsdale, HonorHealth, and Banner network. The scene here skews toward Mayo-trained physicians running longevity and peptide clinics alongside medspas. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Scottsdale clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides sold in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin are FDA-approved for specific indications. In 2023 and 2024, the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which effectively restricts 503A compounding pharmacies from sourcing those ingredients. Section 503A governs traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP standards.
The Arizona State Board of Pharmacy inspects compounding facilities under USP 795 (non-sterile) and USP 797 (sterile) standards. The Board has issued disciplinary actions against pharmacies for sourcing non-compliant bulk ingredients and for sterile compounding deficiencies. Non-resident pharmacies shipping peptides into Arizona must hold a non-resident permit. Clinics sourcing from pharmacies outside the state should verify the pharmacy holds a current Arizona non-resident license.